10-Q: CytomX Reports Q3 Loss Amid Revenue Drop, Bolstered by Capital Raise and Clinical Progress

CytomX Therapeutics reported a significant revenue decline and net loss for the third quarter of 2025, but strengthened its financial position with a recent capital raise and advanced key clinical programs.

Summary

• Revenue for the three months ended September 30, 2025, decreased to $5.96 million from $33.43 million in the prior year, a $27.47 million reduction.
• The company reported a net loss of $14.23 million for the three months ended September 30, 2025, compared to a net income of $5.74 million for the same period in 2024.
• For the nine months ended September 30, 2025, net income was $9.14 million, down from $12.99 million in the prior year.
• Research and development (R&D) expenses decreased by $6.06 million to $15.30 million for the three months ended September 30, 2025, and by $21.10 million to $47.49 million for the nine months ended September 30, 2025.
• General and administrative (G&A) expenses decreased by $1.53 million to $6.43 million for the three months ended September 30, 2025, and by $1.63 million to $22.48 million for the nine months ended September 30, 2025.
• Cash, cash equivalents, and short-term investments totaled $143.6 million as of September 30, 2025, an increase from $100.6 million at December 31, 2024.
• The accumulated deficit was reduced to $682.4 million as of September 30, 2025, from $691.6 million at December 31, 2024.
• A restructuring plan initiated on January 6, 2025, reduced the workforce by approximately 40% and incurred $2.8 million in charges, primarily severance, to prioritize key programs.
• The CX-904 (EGFR product) development program was jointly terminated with Amgen in March 2025, and another Amgen Other Product was terminated in April 2025.
• Positive interim Phase 1 data for CX-2051 in advanced metastatic colorectal cancer showed 28% confirmed partial responses and 94% disease control in efficacy-evaluable patients at higher doses.
• A single Grade 5 treatment-related acute kidney injury occurred in a CX-2051 patient with a complex medical history, reported to the FDA, but study execution and enrollment are ongoing.
• CX-801, a PROBODY interferon, showed promising Phase 1 monotherapy biomarker data, indicating preferential activity in tumors and upregulation of immune checkpoint genes.
• The CX-2029 program was terminated in the first quarter of 2025.
• A new lease for corporate headquarters in Emeryville, California, was entered into in November 2025, commencing October 1, 2026.

Sentiment

Score: 5

Explanation: The sentiment is mixed. While the company experienced a significant revenue decline and a quarterly net loss, and terminated several programs, it successfully executed a substantial capital raise, extending its financial runway. Positive early clinical data for lead assets CX-2051 and CX-801 provide a basis for future potential, but these are offset by a serious adverse event for CX-2051 and delays in some collaboration revenues. The restructuring indicates a strategic focus, but also reflects challenges.

Positives

• Successfully raised approximately $93.4 million in net proceeds from an underwritten public offering in May 2025, significantly strengthening the cash position.
• Net cash used in operating activities decreased to $52.34 million for the nine months ended September 30, 2025, from $66.32 million in the prior year, indicating improved operational efficiency.
• Accumulated deficit decreased by $9.14 million, moving from a stockholders' deficit to a positive equity position.
• CX-2051 demonstrated positive interim Phase 1 data in advanced metastatic colorectal cancer, with 28% confirmed partial responses and 94% disease control in efficacy-evaluable patients at therapeutic doses.
• CX-801 Phase 1 monotherapy biomarker data showed consistent increases in interferon-stimulated genes in tumor biopsies, suggesting preferential tumor activity, and upregulation of immune checkpoint genes.
• Initiated Phase 1 dose escalation for CX-801 in combination with KEYTRUDA in advanced melanoma, indicating progress in a key program.
• Preclinical data for CX-908, a dually masked PROBODY T-cell Engager, showed potent tumor regressions and a 100-fold improvement in tolerability compared to an unmasked molecule.
• Secured a new lease for corporate headquarters, indicating long-term operational planning and stability.

Negatives

• Total revenue for the three months ended September 30, 2025, decreased by $27.47 million (82%) compared to the same period in 2024, primarily due to collaboration terminations and reduced activity.
• The company reported a net loss of $14.23 million for the three months ended September 30, 2025, a significant decline from a net income of $5.74 million in the prior year period.
• The CX-904 program was jointly terminated with Amgen in March 2025, and another Amgen Other Product was terminated in April 2025, leading to a loss of future milestone payments and royalties from these programs.
• The CX-2029 program was terminated in the first quarter of 2025, representing a pipeline reduction.
• Moderna's budget considerations in 2025 are expected to delay the recognition of $9.3 million in deferred revenue primarily to 2026 and 2027.
• A single Grade 5 treatment-related acute kidney injury occurred in a CX-2051 patient, raising safety concerns despite the overall manageable safety profile reported.
• The company is involved in a tax dispute with the state of California regarding revenue apportionment for upfront and milestone payments from 2017 and 2018, with a $4.3 million uncertain tax position recorded.

Risks

• We are a clinical-stage biopharmaceutical company with a limited operating history and have not generated any revenue from product sales.
• We expect that we will need to raise substantial additional funds to advance development of our product candidates and we cannot guarantee that this additional funding will be available on acceptable terms or at all.
• Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
• Our product candidates are in early stages of development and may fail or suffer delays that materially and adversely affect their commercial viability.
• Interim, top-line, initial and preliminary data from our clinical trials, including the ongoing Phase 1 clinical trials of CX-2051 and CX-801, that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
• Our product candidates may cause undesirable side effects at any time during or after the clinical trial process that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, including withdrawal from the market.
• If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.
• We will continue to conduct clinical trials and contract with third-party manufacturers in foreign countries, including Europe and China, which could expose us to risks that could have a material adverse effect on the success of our business.
• Because we have no long-term contracts with and rely on third-party manufacturing and supply partners, most of which are sole source suppliers, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality.
• We, or third-party manufacturers, may be unable to successfully scale-up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing approved products, if any.
• Our approach to the discovery and development of our therapeutic treatments is based on novel technologies that are unproven and may not result in marketable products.
• The market may not be receptive to our product candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of product candidates.
• If our collaborators cease development efforts under our collaboration agreements, or if any of those agreements are terminated, these collaborations may fail to lead to commercial products and we may never receive milestone payments or future royalties under these agreements.
• If we do not achieve our projected development and commercialization goals in the time frames we announce and expect the commercialization of any of our product candidates may be delayed, or never attained, our business will be harmed.
• If we are unable to successfully develop companion diagnostic tests for certain of our product candidates, or experience significant delays in doing so, we may not realize the full commercial potential of our product candidates.
• We rely on third parties to conduct all of our clinical trials and certain of our preclinical studies and intend to continue to do so, and if such third parties do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development programs could be delayed with material and adverse effects on our business, financial condition, results of operations and prospects.
• We face competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms. If these companies develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize product candidates may be adversely affected.
• If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act of 2002 in a timely manner or with adequate compliance, we may be subject to a loss of stockholder confidence and sanctions or investigations by regulatory authorities or litigation.
• Our stock price may be volatile and purchasers of our common stock could incur substantial losses.
• Any future pandemic could adversely impact our business, including our research, development, including clinical trials, manufacturing and financial condition.
• Adverse U.S. and multi-national financial market conditions may adversely affect our business and financial position.
• We may acquire assets or form strategic alliances in the future, and we may not realize the benefits of such acquisitions.
• Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.
• Our information technology systems, or those of our CROs or other contractors or consultants we may utilize, may fail, suffer disruptions or suffer security breaches, which could result in a material disruption of our product development programs.
• The ongoing armed conflict between Russia and Ukraine or other international conflicts could adversely affect our business, financial condition, and results of operations.
• If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.
• Changes in U.S. or foreign tax laws or regulations that are applied adversely to us may have a material adverse effect on our business, cash flow, financial condition or results of operations.
• If securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our stock, our stock price and trading volume could decline.

Future Outlook

Existing capital resources are expected to be sufficient to fund operations into the second quarter of 2027. The company plans to raise additional capital in the future through collaborations, equity offerings, or debt financings. CX-2051 Phase 1 study enrollment is projected to reach approximately 100 patients by the first quarter of 2026, with a data update expected in the same quarter. A Phase 1b study of CX-2051 in combination with bevacizumab is expected to initiate in the first quarter of 2026. Phase 1 clinical data from the CX-801 and KEYTRUDA combination dose escalation study are expected in 2026. Deferred revenue from the Astellas and Regeneron agreements is expected to be recognized until 2026, while Moderna agreement deferred revenue is expected primarily in 2026 and 2027 due to budget considerations.

Management Comments

• Our vision is to transform lives with safer, more effective therapies with the goal to address major unmet needs in oncology.
• We believe we have sufficient capital to operate into the second quarter of 2027.
• We will need to raise additional capital to fund our operation in the future.

Industry Context

The biopharmaceutical industry, particularly oncology, is highly competitive and capital-intensive. CytomX's focus on conditionally activated PROBODY therapeutics represents a novel approach to address toxicities in healthy tissues, a common challenge in cancer treatment. The termination of several collaboration programs and the restructuring reflect a broader industry trend of pipeline prioritization and cost management in response to market conditions and clinical outcomes. The continued development of ADCs, cytokines, and T-cell engagers aligns with major areas of innovation in oncology, with many large and mid-sized biotech companies actively pursuing similar strategies. The regulatory environment, including initiatives like Project Optimus, is increasing the complexity and cost of early-stage oncology drug development.

Comparison to Industry Standards

• The 28% confirmed partial response rate and 94% disease control rate for CX-2051 in late-line colorectal cancer patients (median 4 prior lines of therapy) are encouraging, especially given previous industry efforts targeting EpCAM have struggled with dose-limiting toxicities. This suggests a potentially improved therapeutic index compared to historical EpCAM-targeting agents.
• The preclinical data for CX-908, showing a 100-fold improvement in tolerability and significantly reduced cytokine release compared to an unmasked CDH3xCD3 molecule, positions it favorably against other T-cell engagers which often face challenges with systemic toxicity and cytokine release syndrome.
• The company's reliance on third-party manufacturing, including in Europe and China, exposes it to geopolitical risks and supply chain disruptions, a common challenge for smaller biopharmaceutical companies without in-house manufacturing capabilities, especially with recent legislative proposals like the BIOSECURE Act impacting relationships with Chinese biotechnology companies.
• The reported Grade 5 acute kidney injury for CX-2051, while a single event, highlights the inherent safety risks in oncology drug development, which is a standard concern across the industry for novel potent biologics.

Corporate Governance

Legal Proceedings

• The state of California contested the company's tax position on revenue apportionment for upfront and milestone payments resulting from collaboration and licensing agreements for the years 2017 and 2018. An uncertain tax position of $4.3 million was recorded in long-term liabilities for the proposed assessment, penalties, and interest through September 30, 2025. A protest was filed in November 2023.
• The company is subject to claims and assessments from time to time in the ordinary course of business but is not aware of any such matters, individually or in the aggregate, that will have a material adverse effect on its financial position, results of operations, or cash flows.

Related Party Transactions

• Longitude Venture Partners V, L.P. (LVPV) acquired approximately 11.5 million shares of common stock through the underwritten public offering in May 2025. Longitude Capital Partners V, LLC (LCPV), a general partner of LVPV, has a member on the company's board of directors, making LCPV a related party. No other significant related party transactions with LCPV were disclosed.

Stakeholder Impact

• Shareholders experienced dilution from the May 2025 public offering and ATM sales, but the capital raise extended the company's cash runway, potentially reducing the immediate need for further dilutive financing.
• Employees were significantly impacted by the January 2025 restructuring plan, which resulted in a reduction of approximately 40% of the workforce, primarily through one-time severance payments.
• Collaboration partners like Amgen and Bristol Myers Squibb have terminated certain programs, affecting the company's revenue from these agreements, while others like Astellas, Regeneron, and Moderna continue, albeit with some delays in revenue recognition for Moderna.
• Patients with advanced colorectal cancer may benefit from the continued development of CX-2051, which has shown promising interim Phase 1 efficacy, though the Grade 5 adverse event highlights ongoing safety monitoring needs.
• Patients with advanced melanoma may benefit from the ongoing development of CX-801, particularly in combination with KEYTRUDA, as early biomarker data suggest preferential activity in tumors.

Next Steps

• Continue dose expansion enrollment for CX-2051 monotherapy in advanced colorectal cancer, aiming for approximately 100 patients by Q1 2026.
• Provide a Phase 1 data update for CX-2051 in the first quarter of 2026.
• Initiate enrollment of a Phase 1b study of CX-2051 in combination with bevacizumab in Q1 2026 to inform late-phase development in earlier lines of CRC therapy.
• Continue to evaluate additional non-CRC, EpCAM expressing indications for potential CX-2051 development.
• Present Phase 1 CX-801 monotherapy biomarker data in melanoma patients at the Society of Immunotherapy of Cancer (SITC) 2025 Annual Meeting on November 8, 2025.
• Expect Phase 1 clinical data from the CX-801 and KEYTRUDA combination dose escalation study in 2026.
• Recognize deferred revenue from the Astellas Agreement until 2026.
• Recognize deferred revenue from the Moderna Agreement primarily in 2026 and 2027.
• Recognize deferred revenue from the Regeneron Agreement until 2026.
• Continue to evaluate the impact of ASU 2024-03 (Disaggregation of Income Statement Expenses) for adoption in 2027.
• Adopt ASU 2023-09 (Improvements to Income Tax Disclosures) as of December 31, 2025.
• The new corporate headquarters lease in Emeryville, California, will commence on October 1, 2026.

Key Dates

Recommendation

The company presents a mixed financial and operational picture. While a significant capital raise has improved liquidity and extended the cash runway, the substantial decline in revenue and a quarterly net loss are concerning. The termination of multiple collaboration programs and a serious adverse event in a lead clinical candidate (CX-2051) introduce uncertainty. However, the positive interim efficacy data for CX-2051 and promising biomarker data for CX-801, along with strategic restructuring, suggest potential for future value creation. A 'hold' recommendation is appropriate as investors should monitor the progress of ongoing clinical trials, particularly the safety profile of CX-2051 and the combination data for CX-801, and the company's ability to secure additional collaborations or funding without excessive dilution, before making a more definitive investment decision.

Keywords

Biopharmaceutical, Oncology, PROBODY, Antibody-Drug Conjugates, ADCs, T-cell Engagers, TCEs, CX-2051, EpCAM, Colorectal Cancer, CX-801, Interferon Alpha-2b, IFN2b, Melanoma, Clinical Trials, Drug Development, SEC Filing, Financial Results, Biotech, Capital Raise